scaricalo in formato PDF - labogen srl

Recommendations

Info

Biotin-GA - Labeled GA Analogue Biotin-GA was generated by biotinylation of geldanamycin at the C17 position. This labeled GA can be used to identify novel Hsp90 inhibitors through time-resolved fluorescence resonance energy transfer-based HTS that measures the binding of biotin-GA to the Nterminal ATP-binding domain of Hsp90 10 . 17-AAGH2 & 17-DMAGH2 - Hydroquinone GA Analogues The selective toxicity of benzoquinone ansamycins in tumor cells can be explained by their reduction to hydroquinones. Indeed, many human cancer cells express at high levels NAD(P)H:quinone oxidoreductase 1 (NQO1), a flavoenzyme that catalyzes the direct reduction of quinones to hydroquinones. NQO1 has been shown to reduce 17-AAG and to increase the sensitivity to 17-AAG of cancer cell lines 11 . Recent studies have demonstrated that the reduction product of 17-AAG, 17AAGH2, is a more potent inhibitor of Hsp90 than the 17-AAG itself 12 , as well as 17-DMAGH2 compared to 17-DMAG 13 . InvivoGen provides 17-AAGH2 and 17-DMAGH2 produced by reduction of 17-AAG and 17-DMAG respectively using a chemical reducing agent. Their purity is 99%. www.invivogen.com/inhibitors Biotin-GA C56H88N8O12S MW: 1097 Purity: 99% 1. Whitesell L. et al., 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. PNAS 91(18):8324-8. 2. Neckers L., 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4 Suppl):S55-61. 3. Schulte TW. & Neckers LM., 1998. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4):273-9. 4. Agnew EB. et al. 2001. Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-43. 5. Workman P., 2003. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 3(5):297-300. 6. Egorin MJ, et al., 2002. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49(1):7- 19. 7. Tian ZQ. et al., 2004. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.Bioorg Med Chem. 12(20):5317-29. 8. Mandler R. et al., 2004. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 64(4):1460-7. 9. Mandler R. et al., 2002. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates. Bioconjug Chem. 13(4):786-91. 10. Zhou V. et al., 2004. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem. 331(2):349-57. 11. Kelland LR et al., 1999. DT-Diaphorase expression and tumor cell sensitivity to17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 91(22):1940-9. 12. Guo W et al., 2005. Formation of 17-allylaminodemethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65(21):10006-15. 13. Guo W et al., 2006. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 70(4):1194-203. DNA Synthesis Inhibitors 5-Fluorocytosine - DNA Synthesis Inhibitor 5-Fluorocytosine (5-FC) is a fluorinated cytosine analogue, clinically approved as an antifungal agent. 5-FC is nontoxic to mammalian cells due to their lack of the enzyme cytosine deaminase (CD). CD converts 5-FC into 5-fluorouracil (5-FU), a highly cytotoxic compound routinely used in cancer chemotherapy. 5-FC is used in combination with the E. coli CD gene (codA) or S. cerevisiae CD gene (fcy) in suicide gene therapy protocols 1 . 5-Fluorouracil - Thymidylate Synthase Inhibitor 5-Fluorouracil (5-FU), a fluorinated analogue of uracil, is approved for cancer chemotherapy as an antineoplastic, antimetabolic agent. The cytotoxic effects of 5-FU occur mainly following its conversion to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase. This leads to cell death by DNA synthesis inhibition through deoxythymidine triphosphate deprivation. Ganciclovir - DNA Synthesis Inhibitor Ganciclovir (GCV) is a synthetic analogue of 2'-deoxy-guanosine, clinically approved for the treatment of cytomegalovirus (CMV) infections. GCV is used as a prodrug to obtain a suicide effect in cells transfected with the herpes virus thymidine kinase gene (HSV-tk) 1 . HSV-TK phosphorylates GCV to GCVmonophosphate which is further converted to GCV-diphosphate and GCV-triphosphate by host kinases. GCV-triphosphate causes premature DNA chain termination and apoptosis. The HSV-tk gene and ganciclovir are used in molecular biology for negative selection 2 . 1. Aghi M. et al., 2000. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2(3):148-64. 2. Karreman C., 1998. New positive/negative selectable markers for mammalian cells on the basis of Blasticidin deaminase-thymidine kinase fusions. Nucleic Acids Res. 26(10):2508-10. 159 INHIBITORS 8
9 CUSTOM SERVICES TLR/NOD Ligand Screening 161 Custom-Made CpG-free Genes 161 Custom Cloning 162 Custom-Made psiRNA 162 Custom-Made pDRIVE 162 Large Scale Plasmid DNA Production 163
Page 2 and 3:
INNOVATION WITHIN REACH InvivoGen
Page 4 and 5:
CONTENTS AT A GLANCE 1 CELL CULTURE
Page 6 and 7:
4 CYTOKINE SIGNALING TABLE of CONTE
Page 8 and 9:
Mycoplasma Detection & Elimination
Page 10 and 11:
PlasmoTest Contents - HEK-Blue -2
Page 12 and 13:
Primocin - The Antimicrobial Shiel
Page 14 and 15:
SEAP Reporter Gene System Secreted
Page 16 and 17:
HEK-Blue Detection - Real-Time Det
Page 18 and 19:
Blasticidin S Description Blasticid
Page 20 and 21:
LyoVec New formulation LyoVec is
Page 22 and 23:
Poly-Arginine-HA Tagged Reprogrammi
Page 24 and 25:
LENTI-Smart - Lentiviral Vector Pr
Page 26 and 27:
Lentiviral Vector Production and Ce
Page 28 and 29:
Antibody generation using pFUSE-CHI
Page 30 and 31:
Engineering Fc regions for altered
Page 32 and 33:
pBROAD & pWHERE - Optimized Vector
Page 34 and 35:
pSELECT-Tag - Expression of a GFP-,
Page 36 and 37:
pVIVO - Expression of Two Genes of
Page 38 and 39:
pORF Description pORF plasmids feat
Page 40 and 41:
Prom A-List - Human and Rodent Pro
Page 42 and 43:
PROMOTER GENE TISSUE DISTRIBUTION S
Page 44 and 45:
ChemiComp E. coli ChemiComp E. coli
Page 46 and 47:
Fast-Media ® Preparation 1. Empty
Page 48 and 49:
RIG-I-like Receptors 54 RLR & RLR-R
Page 50 and 51:
Toll-Like Receptors Toll-Like Recep
Page 52 and 53:
www.invivogen.com/innate-immunity 5
Page 54 and 55:
IPAF and NAIP5 IPAF (NLRC4, CLAN/CA
Page 56 and 57:
C-Type Lectin Receptors C-type lect
Page 58 and 59:
pUNO pUNO-HA Toll-Like Receptors (T
Page 60 and 61:
GENE NAME/ALIASES DESCRIPTION CAT.
Page 62 and 63:
pDUO - Gene Associations Features a
Page 64 and 65:
pZERO-TLR & pDeNy - Dominant Negati
Page 66 and 67:
293/TLR & 293/NOD Clones 293/TLR Cl
Page 68 and 69:
Response of HEK-Blue hTLR2 cells t
Page 70 and 71:
Ramos-Blue Cells - NF-kB/AP-1 Repo
Page 72 and 73:
MEF Cells C3H/TLR4mut & C3H/WT MEFs
Page 74 and 75:
Antibodies for Detection ANTIBODY D
Page 76 and 77:
- NF-kB binding site: Nuclear facto
Page 78 and 79:
PRODUCT ORIGIN/DESCRIPTION TLR2 Ago
Page 80 and 81:
PRODUCT ORIGIN/DESCRIPTION TLR9 Ago
Page 82 and 83:
PRODUCT ORIGIN/DESCRIPTION Dectin-1
Page 84 and 85:
LPS-PG (Porphyromonas gingivalis) R
Page 86 and 87:
• FLA-ST ultrapure was purified b
Page 88 and 89:
1. Zhao H. et al., 2004. Contributi
Page 90 and 91:
1. Hornung V. et al., 2006. 5'-Trip
Page 92 and 93:
TLR/NOD Ligand Screening InvivoGen
Page 94 and 95:
Signal Transduction Inhibitors Invi
Page 96 and 97:
Pepinh-MYD - MyD88 inhibitory pepti
Page 98 and 99:
1. Martinon F,. et al., 2002. The i
Page 100 and 101:
Nigericin - NLRP3 Inflammasome Indu
Page 102 and 103:
Autophagy is a pathway by which cyt
Page 104 and 105:
4 CYTOKINE SIGNALING Cytokine Genes
Page 106 and 107:
Blue Cytokine Reporter Cells Blue
Page 108 and 109:
HEK-Blue IFN-a/b Cells - Human Typ
Page 110 and 111: HEK-Blue IL-6 Cells - IL6 Reporter
Page 112 and 113: HEK-Blue IL-1b Cells - IL-1b Repor
Page 114 and 115: HEK-Blue IL-33/IL-1b Cells - IL-33
Page 116 and 117: HEK-Blue CD40L Cells - CD40L Repor
Page 118 and 119: 5 ANTIBODIES & VACCINATION Antibodi
Page 120 and 121: Antibody generation using pFUSE-CHI
Page 122 and 123: Immunoglobulin A The mucosal surfac
Page 124 and 125: IgA Detection and Quantification In
Page 126 and 127: IgG Antibodies InvivoGen offers a s
Page 128 and 129: Mediators? 1. Leroux-Roels G., 2010
Page 130 and 131: Poly(I:C) Synthetic double-stranded
Page 132 and 133: pVAC - Induction of Neutralizing An
Page 134 and 135: CpG-Free DNA CpGs and the Immune Re
Page 136 and 137: pCpGfree-basic & pCpGfree-promoter
Page 138 and 139: pCpGfree-siRNA & pCpGfree-siRNADUO
Page 140 and 141: Custom-Made CpG-Free Genes InvivoGe
Page 143 and 144: RNA INTERFERENCE 7 psiRNA System I
Page 145 and 146: RNA INTERFERENCE 7 psiRNA-h7SK - 7S
Page 147 and 148: RNA INTERFERENCE 7 psiTEST System
Page 149 and 150: RNA INTERFERENCE 7 Ready-Made psiRN
Page 151 and 152: RNA INTERFERENCE 7 Custom-Made psiR
Page 153 and 154: INHIBITORS 8 Inhibitors PRODUCT DES
Page 155 and 156: INHIBITORS 8 Pattern Recognition Re
Page 157 and 158: INHIBITORS 8 Triptolide - NF-kB Inh
Page 159: INHIBITORS 8 Heat Shock Protein Inh
Page 163 and 164: CUSTOM SERVICES 9 Custom Cloning :
Page 165 and 166: CUSTOM SERVICES 9 Prices 164 TERMS
Page 167 and 168: 166 PRODUCT (QUANTITY) CAT. CODE PA
Page 173 and 174: A 17-AAG 17-AAGH2 17-AEP-GA 2-Amino
Page 175 and 176: - ODN 4084-F - ODN INH-1 - ODN INH-
Page 177 and 178: ARGENTINA Genbiotech S.R.L. Tel: +5
show all

scaricalo in formato PDF - labogen srl

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?